| Literature DB >> 34046629 |
Ingrid Allart-Simon1, Aurélie Moniot2, Nicolo Bisi1, Miguel Ponce-Vargas1, Sandra Audonnet3, Marie Laronze-Cochard1, Janos Sapi1, Eric Hénon1, Frédéric Velard2, Stéphane Gérard1.
Abstract
Cyclic nucleotide phosphodiesterase type 4 (PDE4), which controls the intracellular level of cyclic adenosine monophosphate (cAMP), has aroused scientific attention as a suitable target for anti-inflammatory therapy of respiratory diseases. This work describes the development and characterization of pyridazinone derivatives bearing an indole moiety as potential PDE4 inhibitors and their evaluation as anti-inflammatory agents. Among these derivatives, 4-(5-methoxy-1H-indol-3-yl)-6-methylpyridazin-3(2H)-one possesses promising activity, and selectivity towards PDE4B isoenzymes and is able to regulate potent pro-inflammatory cytokine and chemokine production by human primary macrophages. This journal is © The Royal Society of Chemistry.Entities:
Year: 2021 PMID: 34046629 PMCID: PMC8127987 DOI: 10.1039/d0md00423e
Source DB: PubMed Journal: RSC Med Chem ISSN: 2632-8682